Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Radioimmunotherapy is rapidly developing to clinically efficient therapy].

L Stenke1, R Lewensohn, J Carlsson

  • 1Centrum för hematologi, medicindivisionen, Karolinska sjukhuset, Stockholm. leif.stenke@kids.ki.se

Lakartidningen
|February 25, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study.

Leukemia·2026
Same author

Conservation implications of low contemporary connectivity along the Mid-Atlantic Ridge in hydrothermal vent gastropods.

Conservation biology : the journal of the Society for Conservation Biology·2026
Same author

Adaption and validation of the Rwandese version of the Young Mania Rating Scale to measure the severity of a manic or hypomanic episode.

BMC psychiatry·2024
Same author

Adaption and validation of the Rwandese version of the Mood Disorder Questionnaire for the screening of bipolar disorder.

Comprehensive psychiatry·2024
Same author

Group psychoeducation for persons with bipolar disorder in Rwanda: a study protocol for a randomized controlled trial.

Trials·2022
Same author

Intervention trials for adults with bipolar disorder in low-income and lower-middle-income countries: A systematic review.

Journal of affective disorders·2022

Monoclonal antibodies (mAbs) show promise in cancer therapy, especially for non-Hodgkin lymphoma. Radioimmunotherapy, using radiolabeled mAbs, offers targeted radiation delivery to cancer cells while sparing healthy tissue.

Area of Science:

  • Oncology
  • Immunology
  • Radiochemistry

Context:

  • Monoclonal antibodies (mAbs) are increasingly recognized for their therapeutic potential in oncology.
  • Recent advancements include improved target antigen definition and humanized mAbs, reducing adverse immune responses.
  • The conjugation of mAbs with radionuclides is a key development in targeted cancer therapy.

Purpose:

  • To review the advancements and clinical applications of monoclonal antibodies in cancer therapy.
  • To explore the principles and potential of radioimmunotherapy for targeted radiation delivery.
  • To discuss the selection criteria for mAbs and radionuclides, clinical data, and future prospects in radioimmunotherapy.

Summary:

  • Monoclonal antibodies (mAbs) are showing significant clinical responses, particularly in low-grade non-Hodgkin lymphoma.

Related Experiment Videos

  • Radioimmunotherapy (RIT) utilizes radiolabeled mAbs for targeted systemic radiation delivery to cancerous tissues, minimizing damage to normal tissues.
  • RIT can be administered as single high doses or multiple smaller fractions, with careful selection of mAbs and radionuclides being crucial for efficacy.

    • Impact:

    • Enhanced efficacy in treating cancers like non-Hodgkin lymphoma.
    • Potential for reduced side effects compared to conventional therapies.
    • Opens new avenues for personalized cancer treatment through targeted radiation delivery.